These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28346297)

  • 1. Exposure to Mycophenolate and Fatherhood.
    Midtvedt K; Bergan S; Reisæter AV; Vikse BE; Åsberg A
    Transplantation; 2017 Jul; 101(7):e214-e217. PubMed ID: 28346297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of mycophenolic acid is not associated with malformations in descendants from kidney transplanted males.
    Lopez-Lopez I; Rodelo-Haad C; Agüera ML; Cabello-Jabalquinto R; Esquivias-Motta E; Navarro MD; Aljama P; Rodriguez-Benot A
    PLoS One; 2018; 13(9):e0202589. PubMed ID: 30208043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reassuring results on birth outcomes in children fathered by men treated with azathioprine/6-mercaptopurine within 3 months before conception: a nationwide cohort study.
    Nørgård BM; Magnussen B; Larsen MD; Friedman S
    Gut; 2017 Oct; 66(10):1761-1766. PubMed ID: 27456154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limits to intensified mycophenolate mofetil dosing in kidney transplantation.
    Kiberd BA; Lawen J; Daley C
    Ther Drug Monit; 2012 Dec; 34(6):736-8. PubMed ID: 23007746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intractable ascites associated with mycophenolate in a simultaneous kidney-pancreas transplant patient: a case report.
    Weber NT; Sigaroudi A; Ritter A; Boss A; Lehmann K; Goodman D; Farese S; Weiler S; Mueller TF
    BMC Nephrol; 2017 Dec; 18(1):360. PubMed ID: 29233098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study.
    Yin H; Qiu K; Hu XP; Li XB; Wang W; Liu LH; Zhang XD
    Int J Clin Pract Suppl; 2014 Apr; (181):31-7. PubMed ID: 24673717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
    Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H;
    Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obstetric and neonatal outcome of pregnancies fathered by males on immunosuppression after solid organ transplantation.
    Morken NH; Diaz-Garcia C; Reisaeter AV; Foss A; Leivestad T; Geiran O; Hervás D; Brännström M
    Am J Transplant; 2015 Jun; 15(6):1666-73. PubMed ID: 25868657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients.
    Graff J; Scheuermann EH; Brandhorst G; Oellerich M; Gossmann J
    Ther Drug Monit; 2016 Jun; 38(3):388-92. PubMed ID: 26829599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation.
    van Gelder T; Silva HT; de Fijter H; Budde K; Kuypers D; Mamelok RD; Armstrong VW; Oellerich M
    Ther Drug Monit; 2011 Apr; 33(2):155-64. PubMed ID: 21383657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
    Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
    Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paternal safety of the use of mycophenolic acid in kidney transplant recipients. Results of the EMVARON study.
    Martin-Moreno PL; Sánchez-Fructuoso AI; Mazuecos A; Mir M; Lopez-Lopez I; González-Rinne A; Coca A; Valero R; Ventura Galiano A; Ridao N; Toapanta-Gaibor NG; Fernández-Tagarro E; Cruzado-Vega L; Pérez-Mir M; Jiménez C
    Clin Transplant; 2021 May; 35(5):e14256. PubMed ID: 33599030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of pregnancies fathered by solid-organ transplant recipients exposed to mycophenolic acid products.
    Jones A; Clary MJ; McDermott E; Coscia LA; Constantinescu S; Moritz MJ; Armenti VT
    Prog Transplant; 2013 Jun; 23(2):153-7. PubMed ID: 23782663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolic acid dose reductions result in poor long-term renal allograft survival: comparison between mycophenolate sodium and mycophenolate mofetil.
    Laftavi MR; Hai F; Laftavi H; Feng L; Said M; Patel S; Kohli R; Alnimri M; Dayton M; Pankewycz O
    Transplant Proc; 2011 Mar; 43(2):478-81. PubMed ID: 21440738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation.
    Roan JN; Chou CH; Hsu CH; Wu SY; Huang YC; Yang YJ; Luo CY
    Ann Transplant; 2013 Feb; 18():43-52. PubMed ID: 23792500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.